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Abstract
Advancements in molecular biology have unveiled multiple breast cancer promoting pathways and potential therapeutic
targets. Large randomized clinical trials remain the ultimate means of validating therapeutic efficacy, but they require large
cohorts of patients and are lengthy and costly. A useful approach is to conduct a window of opportunity study in which
patients are exposed to a drug pre-surgically during the interval between the core needle biopsy and the definitive surgery.
These are non-therapeutic studies and the end point is not clinical or pathological response but rather evaluation of
molecular changes in the tumor specimens that can predict response. However, since the end points of the non-therapeutic
studies are biologic, it is critical to first define the biologic changes that occur in the absence of treatment. In this study, we
compared the molecular profiles of breast cancer tumors at the time of the diagnostic biopsy versus the definitive surgery in
the absence of any intervention using the Nanostring nCounter platform. We found that while the majority of the
transcripts did not vary between the two biopsies, there was evidence of activation of immune related genes in response to
the first biopsy and further investigations of the immune changes after a biopsy in early breast cancer seem warranted.
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Introduction
Window of opportunity clinical trials or non-therapeutic studies
in breast cancer are studies that exploit the time interval between
the diagnostic core needle biopsy (CNB) and definitive surgery for
a brief exposure to a study drug. As opposed to neoadjuvant
studies, in which patients are given an investigational therapy for a
prolonged period of time and the end point is usually clinical or
pathological response, the intervention in window of opportunity
studies is brief and the goal is not therapeutic but rather the
biological changes that occur in response to the intervention. This
model of clinical investigation cannot replace the gold standard
large randomized adjuvant trials, which provide important data
about long-term exposure to a given agent, particularly data about
toxic effects. However, in an era where only a tenth of new
targeted agents that enter clinical development are approved by
the US Food and Drug Administration [1], window of opportunity
studies can serve as a relatively rapid and low-cost tool to exclude
ineffective agents from further development and validate markers
that can define a subset of patients that benefit most from a new
agent or novel combinations of agents. Moreover, this approach
allows access to tumor tissues before and after treatment in close to
100% of enrolled patients.
Over 75% of breast cancers are estrogen receptor positive (ER+)
and despite effective endocrine treatments, most breast cancer-
related deaths occur within this sub-group of patients [2]. This
underscores the need for new-targeted agents combined with
hormonal blockade to improve outcomes in patients with early
ER+ breast cancer. The investigation of new agents for early ER+
breast cancer requires prolonged follow-up and very large sample
sizes because of the low annual risk of recurrence but protracted
risk over several decades. Thus, window of opportunity studies
have the potential to be an important modality for the study of
hormonal blockade combined with new agents targeting ER+
breast cancer. The IMPACT (Immediate Preoperative Anastra-
zole, Tamoxifen, or combined with Tamoxifen) trial is one of the
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first studies to show early molecular changes in ER+ breast cancer
after a brief exposure to hormonal treatment. In this study, 330
post-menopausal women were randomized to 12 weeks of pre-
operative anastrazole, tamoxifen or anastrazole combined with
tamoxifen. Ki67 was selected as the primary biomarker end-point
and changes in Ki67 levels were detected after just two weeks of
treatment. The level of Ki67 suppression differed between the
anastrazole and tamoxifen arms and mirrored the recurrence free
survival results of the ATAC (Arimidex, Tamoxifen Alone or in
Combination) adjuvant trial [3,4]. Furthermore, in a later analysis,
Ki67 levels at a two week point correlated with recurrence free
survival suggesting that the early changes in Ki67 after a brief
exposure to endocrine treatment is indicative of long term
outcomes [5].
Other window of opportunity studies using novel agents in ER+
breast cancer have been published recently [6–9]. One such study
investigated a short exposure to presurgical erlotinib in newly
diagnosed breast cancers and showed that in ER+ breast cancers
and not HER2+ or triple negative disease, there was a reduction in
the phosphorylation of both ER at the S118 site and of MAPK as
well as a Ki67 response that was not dependent on EGFR
positivity. This study suggests that erlotinib is worthy of further
investigation in ER+ breast cancers and not Her2 positive or triple
negative breast cancers and EGFR positivity does not necessarily
predict response [6].
Non-therapeutic studies have several drawbacks; while the Ki67
marker has been extensively studied and incorporated into such
studies and is a also a key component of Oncotype Dx and other
multi-gene expression prognostic test [10,11], it is not a useful
biomarker of response for all types of targeted treatments, e.g.
agents that target angiogenesis or apoptosis. Moreover, in most
studies Ki67 is quantified by immunohistochemistry, which is an
assay that is prone to both technical errors and interpretation bias.
Hence, additional biomarkers that can predict treatment responses
and long-term outcomes as well as assays that are highly
reproducible and quantitative are needed. In addition, since the
end point of window of opportunity studies is molecular changes it
is critical to define gene expression variations between core
biopsies and excisional biopsies in the absence of drug exposure.
Such variations may occur due to smaller sampling size in the core
biopsies and tumor heterogeneity, differences in tissue handling
and processing or as a result of the core biopsy itself. The aims of
this study were to determine if there are variations in gene
expression levels between core biopsies of early breast cancer
specimens compared to the matched excisional biopsies (EB) in the
absence of any intervention using a highly reproducible and
quantitative assay, the Nanostring nCounter system, and study the
correlation between clinical immunohistochemistry protein ex-
pression levels and the Nanostring transcript expression level
[12,13]
Materials and Methods
Ethics statement
The prospective collection of breast cancer tissue samples from
core biopsies and excisional biopsies was done with patient consent
and the Dana Farber/Harvard Cancer Center Institutional
Review Board approval under protocol #07-104.
Patient samples
Tissue was collected from post-menopausal women with newly
diagnosed breast cancer with a primary tumor larger than 1 cm on
the basis of physical exam or imaging. At the time of a diagnostic
core biopsy, 2–4 extra core needle biopsies with a 14-gauge needle
were obtained and immediately snap frozen in 2-methyl-butane in
Optimal Cutting Temperature Compound. Patients who were
diagnosed with invasive carcinoma underwent definitive surgical
resection and at that time a paired specimen was obtained and
snap frozen. Presence of invasive cells was verified by hematoxylin
and eosin staining and RNA was isolated using Trizol (Invitrogen)
in accordance with the manufacturer’s instructions.
NanoString nCounter analysis
RNA concentration was measured with the Nanodrop 1000
(Nanodrop). Color coded barcodes that represent a single target
transcript were synthesized targeting 147 breast cancer related
genes and 6 control housekeeping genes (Nanostring technologies).
The barcodes were hybridized overnight to 100 ng of total RNA
in a reaction that includes a hybridization buffer and a capture
probe. The latter enables the immobilization of the complex for
data collection. Following incubation, samples were placed on a
prep station where excess probes were removed and the probe-
transcript complexes were immobilized on a streptavidin coated
cartridge. Subsequently the cartridges were placed in the Digital
Analyzer and barcodes were counted and tabulated. Each count
represents one molecule. Raw nanoString counts were subjected to
a technical normalization using positive control spikes that corrects
for any experimental variables between the samples (e.g.
differences in efficiency in hybridization, purification or binding).
This normalization is done by multiplying all counts by a
normalization factor that is calculated by the average of the sum
of the counts for all positive hybridization controls for each sample
divided by the sum for each sample. The normalization factor was
between 0.3–3 (within the required range). Data is also normalized
for RNA content using housekeeping genes and multiplying all
counts by a calculated normalization factor. Because of the
potential variability in the expression of housekeeping genes, in
order to optimize the normalization, multiple housekeeping genes
were used including genes with high and low expression (CLTC,
GAPDH, GUSB, HPRT1, PGK1, TUBB). This normalization
factor is calculated by the average of the geometric mean of all the
housekeeping gene counts for each sample divided by the
geometric mean of each sample. The normalization factors ranged
between 0.3–7.6 (for valid data the values are required to be within
a range of 0.1–10). Nanostring count levels of the housekeeping
genes are shown in table S1. Additionally, there are eight codes
that have no transcript that are used as negative controls for
background noise by subtracting the average of the negative
controls from the normalized gene counts.
Immunohistochemistry
Immunohistochemistry was performed on formalin fixed
paraffin embedded sections. The antibodies used were as follows:
ER (Neomarkers), PR (Dako), HER2 (Dako), Ki67 (Vector Labs
VP-RM04) and CD68 (Dao M0876). Nuclei were counterstained
with hematoxylin. The staining was performed by the pathology
department at Beth Israel Deaconess Medical Center and the
Dana Farber/Harvard Cancer Center research pathology core.
All samples also had FISH analysis for HER2 amplification. A
HER2/cen17 ratio above 2.2 was considered positive. All samples
were reviewed by a pathologist and scoring for ER as follows; zero
percent positive cells among all invasive cells was scored as
negative, 1–10% low positivity and above 10% is positive.
Scoring of the immunohistochemistry staining of Ki67 was done
by counting at least 1000 invasive tumor cells in at least three
different high power fields and in accordance with published
guidelines [14]. The score was expressed as the percentage of
positively staining cells among the total number of invasive tumor
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cells in the area. Assessment of CD68 was also done by counting at
least 1000 invasive tumor cells in three different fields and scoring
is the percentage of positive cells among the total number of
invasive tumor cells.
Real-time PCR
Equal amounts of RNA were used as templates for cDNA
synthesis using the Applied Biosystems kit and PCR reactions were
carried out using an ABI Prism 7700 Sequence Detection System
(Applied Biosystems). The fold change expression between the
core biopsy and excisional biopsy for each gene was calculated
using the DDCt method with GAPDH mRNA as an internal
control. The primers used are shown in table S4.
Statistical Analysis
Differences in protein and mRNA transcript expression levels
between the core and excisional biopsies were assessed using
Wilcoxon signed rank tests. Spearman correlation coefficients
quantified the correlation between measures protein and transcript
expression levels. The association of the difference in gene
Table 1. Clinical characteristics of the participating patients.
Category Sub-Category No. of Patients (%) Years Days
A`ge Mean 68
Range 52–86
Interval Between Biopsies Mean 30
Range 6–65
Definite Surgery Lumpectomy 17 (80)
Mastectomy 4 (20)
Tumor Grade I 2 (10)
II 12 (60)
III 7 (30)
Tumor Stage I 7 (30)
II 11 (60)
III 3 (10)
Tumor Classification Hormone receptor + 18
HER2 + 3
Triple negative 2
doi:10.1371/journal.pone.0064225.t001
Figure 1. Correlation between CNBs clinical data and Nanostring nCounter expression values. Color coding- green represents low
nanostring expression level and red represents high nanostring expression level. Expression levels are log transformed. A. ER+/HER2 negative breast
cancers had high ER expression and low HER2 Nanostring expression, HER2 positive tumors displayed high ERBB2 expression levels and triple
negative (TN) cancers had low ER and HER2 expression levels. E = ER, P = PR, H=Her2. B. Ki67 high defined as an IHC score of above 14% and low as
#14%. Scatter plot showing correlation between the Nanostring Ki67 expression level (Y axis) and IHC Ki67 score (x-axis).
doi:10.1371/journal.pone.0064225.g001
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expression between biopsies and the length of the time interval
between the biopsies (more than or less than 1 month) was
evaluated using Wilcoxon’s rank sum tests.
Clustering
Unsupervised clustering analyses were performed with MeV 4.8
(http://www.tm4.org/mev/) using Pearson correlation with
average linkage clustering.
Results
Sufficient RNA was collected from 23 matched pairs of cores
and excisions. Nanostring nCounter gene expression analysis was
successful in 21 of the paired biopsies and all the analyses in this
study were done on these tumors. All patients were post-
menopausal and as expected the majority had ER positive breast
cancers. 60% of the patients had stage II disease and grade II
disease and 80% of the patients underwent a partial mastectomy as
definitive surgery. Further details are shown in table 1.
Because this study focused on ER+ breast cancers we assembled
a list of 147 transcripts to be quantified, which consists of genes
that are related to the ER transcriptional network. Included are
genes that are ER target genes (e.g. PR, Cyclin D1, XBP1), ER
regulators (e.g. AIB1, FOXA1, GATA3), genes that have been
implicated in endocrine resistance (e.g. EGFR, HER2, Insulin –
like-receptor, PI3K), inflammatory genes and additional related
genes [15–20]. The list also includes the 16 genes of the Oncotype
DX recurrence score and the 50-gene breast cancer intrinsic sub-
type classifier (PAM50), since both of these assays have prognostic
and predictive properties in ER positive breast cancers [10,21,22].
We profiled the RNA extracted from the cores and excisions in the
42 samples using the Nanosting nCounter system. This system is as
sensitive as RT-qPCR and does not require the conversion of
RNA to cDNA. The full list of genes and normalized data is in
table S1. As an internal control we compared the digital transcript
counts for ESR1 (encoding ER), PGR (encoding Progesterone
Receptor (PR)) and ERBB2 (encoding HER2) to the clinical ER,
PR and HER2 status, and these were highly associated (figure 1A).
Ki67 score in both the cores and excisions also highly correlated
Figure 2. Heatmap of unsupervised clustering of both the CNB and EB samples. Heatmap of unsupervised clustering of all the samples and
all the transcripts. All of the CNB and EB pairs co-aggregated at the first level dendrogram.
doi:10.1371/journal.pone.0064225.g002
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with the Nanostring MKI67 expression (Cores, Spearman
r= 0.62, P = 0.02; excisions, Spearman r= 0.60, P= 0.02)
(figure 1B). These results validate the integrity of the acquired
gene expression data.
The samples were clustered in order to determine whether core
and excisional biopsies aggregated together as nearest neighbors in
clustering dendrograms. All the paired samples of cores and
excisions co-aggregated at the first level dendrogram (figure 2).
Additionally, when we clustered the samples using just the 16
Oncotype Dx genes, 18/21 (85%) of the paired samples co-
aggregated at the level of the first dendrogram (figure 3).
Clustering of the samples by the PAM50 gene set yielded similar
results with 19/21 of the paired samples co-aggregating (figure 4).
Although, in this study we used the Nanostring for gene expression
analysis and not quantitative reverse-transcriptase PCR as done in
the Oncotype Dx and PAM50 studies, our results imply that the
expression of the genes that comprise the Oncotype Dx score and
the risk of relapse (ROR) score may be comparable between a core
biopsy and excisional biopsy.
We next analyzed each of the 147 genes individually and used
the Wilcoxon’s signed rank test to compare the Nanostring
expression level between the core and excisional biopsy (complete
analysis in table S2). The majority of the genes, including MKI67
(Ki67) did not differ significantly between the core and excisional
biopsies without therapeutic intervention. However, there were 14
genes that did significantly differ (p,0.05) as shown in figure 5. Of
the 14 genes 9 have functions that are immune related, consisting
of: markers of macrophages and monocytes (CD68, CD14),
markers of lymphocytes or lymphocyte activation (CD52, CD44),
cytokines or other factors that either activate immune cells or are
modulated by immune related signals (IL6, PPARG, ADM,
IGFBP2, VEGFA) [23–27]. The digital expression level of all of
these nine immune related transcripts increased in the excisional
biopsy compared to the matched core biopsy. The increase in the
expression levels of three of the immune related transcripts (CD68,
CD52 and CD14) was also validated by real-time PCR (figure S1).
The increased expression of immune related genes in the excisions
is likely due to an inflammatory response to the core biopsy itself
and not because of intra-tumoral heterogeneity. This is supported
by the comparison of the scatter plots of the Nanostring gene
expression levels obtained from multiple biopsies taken from the
same tumor specimen at the same time point but from different
sites, which did not reveal any difference in gene expression levels,
as shown in additional file, figure S2. However due to limited
sample size no hypothesis testing was done to assess the difference
in gene expression level between these biopsy samples. Impor-
tantly, the increases in expression of CD68 and the other immune
related genes were not related to the time interval between the
CNB and EB (additional file, table S3).
In order to corroborate the results of the Nanostring transcript
expression level with protein expression we performed immuno-
histochemistry staining for Ki67 and CD68 in 14 of the CNBs and
Figure 3. Heatmap of unsupervised clustering of the CNB and EBS using the Oncotype Dx genes. Unsupervised clustering heatmap of all
samples using the Oncotype Dx genes only. 18 of the 21 paired biopsies co-aggregated in the first level dendrogram. Lower heatmap shows the
Nanostring expression levels of the control housekeeping genes.
doi:10.1371/journal.pone.0064225.g003
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matched EBs. We chose CD68, because the Nanostring expression
level of this gene was most significantly increased in the EBs
compared to the CNBs. We detected higher CD68 positive cells in
the EBs compared to the CNB (median difference 5.4, IQR 1.6 to
7.4; P = 0.0002) and no significant difference in Ki67 (median
difference 21.0, IQR 23.4 to +2.2; P = 0.63), which is consistent
with the transcript expression levels (Figure 6). Interestingly, the
recruitment of the CD68 positive cells, which are tumor-associated
macrophages (TAMs), is seen mainly among the invasive tumor
cells and to a lesser extent in the associated stroma.
Discussion
A CNB followed by a short interval and definitive surgery is the
standard practice in the care of early stage breast cancer patients.
This time interval provides an opportunity for trials involving a
brief exposure to new agents with the goals of validating the ability
of the agent to hit its target and for the identification of potential
biomarkers that can predict responsiveness to the drug. Several
such studies, defined as window of opportunity studies or non-
therapeutic studies, have already been completed and have used
the Ki67 changes as a surrogate marker for response and as the
primary aim. Some of these studies did not include a control arm
to validate that the biological changes seen after a brief exposure to
a specific agent are indeed due to the exposure and not variations
due to sampling differences. The notion that gene expression
variations may exist between CNB and EBs is buttressed by the
controversial data derived from multiple studies that investigated
the concordance of the hormone receptor (HR) status (ER and PR)
in CNBs compared to EBs [28–30]. A recent meta-analysis of 21
articles showed that overall the agreement between the CNB and
Figure 4. Heatmap of unsupervised clustering of the CNB and EBS using the PAM50 genes. Unsupervised clustering heatmap of all
samples using the PAM50 genes only. 19 of the 21 paired biopsies co-aggregated in the first level dendrogram.
doi:10.1371/journal.pone.0064225.g004
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EB was high, but there was a meaningful difference in the
expression levels of HR markers determined by immunohisto-
chemistry, particularly for PR (7.2% and 14.8% discordance for
ER and PR, respectively) [31]. To our knowledge, a large-scale
analysis of the variations in gene expression between CNB and EB
without any intervention has not been conducted and this was the
aim of this study.
We compared CNBs and EBs collected prospectively from 21
patients with newly diagnosed early stage breast cancer. All
patients were postmenopausal and the majority had HR positive
disease. We studied the quantitative expression levels of 147 breast
cancer associated transcripts using the Nanosting nCounter
platform and found that for the majority of the transcripts there
was high concordance between the CNBs and EBs. The list of
transcripts included in this study comprised of genes with known
functions in the ER transcriptional program, ER resistance
pathways and genes with prognostic significance in HR positive
tumors, since these genes have the potential to also have predictive
properties for novel treatments in HR positive tumors. MKI67
(Ki67) is a key transcript in this analysis since it has been shown to
be a prognostic factor in breast cancer and the change in Ki67
after a short exposure to hormonal therapy has been shown to be
predictive of long term outcomes in HR positive tumors though
this has not been validated in the other sub-types of breast cancer.
In our study we did not find Ki67 variability between the CNB
and EB without any treatment at the RNA and protein expression
levels and therefore, changes seen in Ki67 levels after a brief
exposure to a treatment, are likely due to the exposure and not
because of differences in sampling.
Our study is notable for significant differences between CNBs
and EBs in the expression level of 14 transcripts of which the
majority are immune related. Of particular interest is the
difference in CD68, a marker for TAMs. In human breast
tumors, infiltrating TAMs correlate with poor prognostic features,
higher tumor grade and decreased disease free survival [32,33].
This may be, in part due to increased angiogenesis that has been
shown in mouse models of mammary gland tumors and in human
breast tumors where CD68 levels correlate with VEGF expression
[34,35]. In a recent study, blockade of TAMs recruitment in
addition to chemotherapy in mammary tumors in MMTV-
polyoma middle T antigen mice led to a reduction in primary
tumor progression and metastasis and improved survival [36].
Figure 5. Changes in the expression levels of immune related genes between CNBs and EBs. A. Individual patient plots (n = 21) for
NanoString expression level at the time of the CNB and EB for Ki67, CD68, and VEGFA. P-values are from Wilcoxon signed rank tests. B. Bar graph
represents the Nanostring expression value differences between the CNB and EBs for all the genes that had a statistically significant change (by
Wilcoxon signed rank tests). * denotes genes with immune related functions.
doi:10.1371/journal.pone.0064225.g005
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Thus, targeting TAMS is a potential new approach for breast
cancer treatment and the increase in CD68 and other immune
related genes between the CNBs and EBs has several implications;
first, window of opportunity clinical trials for immune modulating
drugs and in general, changes in immune related genes after
exposure to a drug may be difficult to interpret due to the
inflammatory changes that are unrelated to drug exposure as
shown in this study. Second, although our study is limited as we
studied a relatively small number of immune related genes and the
immune microenviroment in breast cancer is complex, the
recruitment of CD68 positive TAMs after a CNB raises the
concern that this recruitment may occur after each breast cancer
biopsy. This raises the question of whether CNB may have a
deleterious effect on outcome through the stimulation of the
recruitment of TAMs and this is of particular concern as many
neoadjuvant clinical trials include additional biopsies. Hence,
studies of the immune effects of multiple biopsies in early stage
disease seem warranted.
Conclusions
In summary, although this study has limitations because of the
number of patients and number of transcripts evaluated, we show
that overall there are not many gene expression variations between
CNBs and EBs and therefore the differences in the sampling
methods between these two types of biopsies is not a significant
drawback for window of opportunity studies. However, even in
this small study we were able to detect significant differences in the
expression of immune related genes that will need to be considered
when interpreting window of opportunity studies. We also found a
strong correlation between the clinical data, based on immuno-
histochemistry staining and established guidelines and the Nano-
string nCounter expression value, suggesting that this platform
could be a useful tool in clinical studies that incorporate gene
expression analysis.
Supporting Information
Figure S1 Increase in expression of immune related
genes in the EB validated by RT-PCR. The fold change
between CNB and EB of the expression of immune related genes
(CD68, CD52, CD14) compared to non-immune related genes
(ESR1, ERBB2, MKI67, PTEN) was significantly higher in the
immune related genes (p,0.001, Student’s t-test).
(TIF)
Figure S2 Multiple same time biopsies in individual
patients. Logged expression values of the 14 genes that were
significantly different between the CNBs and EBs in biopsies
Figure 6. Immunohistochemistry analysis of CNBs and EBs. a and b represent Ki67 staining of CNB and EB respectively and c and d represent
CD68 staining in a CNB and EB. Magnification 206. A. Box plots of the Immunohistochemistry scoring for Ki67 and CD68 in the CNB samples and EBs.
doi:10.1371/journal.pone.0064225.g006
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obtained from different sites at the same time from 3 individual
patients.
(TIFF)
Table S1 Nanostring gene expression analysis. Normal-
ized nanostring gene expression values for the 147 transcripts.
(DOCX)
Table S2 Gene expression differences between CNB
and EB. The table includes the mean, median and standard of
change between the biopsies and the p-values for the Wilcoxon’s
signed rank test.
(XLSX)
Table S3 The increase in immune responsive gene
expression at the time of the EB is not dependent on
the time interval between the CNB and EB. Wilcoxon’s
rank sum tests were performed to evaluate the association of the
difference in gene expression between the two biopsies and the
time interval between the biopsies. The time interval is
dichotomized at 1 month.
(DOCX)
Table S4 Oligonucleotide primer sequences used for
RT-PCR.
(DOCX)
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